★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
ResMed Inc. (RMD) Moat Analysis
ResMed Inc.
RMD · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Resmed sells sleep and breathing devices, masks, connected monitoring, and residential-care software. Its device franchise benefits from recurring replacement demand, provider workflow integration through AirView and myAir, and clinical reputation. The consumables moat is moderate because patients can switch complete mask systems. Residential Care Software has workflow switching costs, but management describes low entry barriers and intense competition. FY2026 revenue grew 10% to $5.653 billion, with an 88.0% device and 12.0% software mix. Masks-and-other revenue rose 13% to $2.085 billion. Resmed agreed to sell MatrixCare for $490 million; its roughly $220 million of FY2026 revenue remains in historical software results pending the expected Q1 FY2027 close. Philips competition, reimbursement pressure, interoperability, cybersecurity, and alternative apnea therapies are the main risks.
Primary segment
Sleep and Breathing Health
Market structure
Oligopoly
Market share
58%-66% (estimated)
HHI: —
Coverage
2 segments · 6 tags
Updated 2026-08-23
Segments
Sleep and Breathing Health
Sleep apnea and respiratory care devices and related consumables (PAP, masks, ventilation) plus connected monitoring services
Revenue
88%
Structure
Oligopoly
Pricing
moderate
Share
58%-66% (estimated)
Peers
Residential Care Software
Out-of-hospital care provider software (HME/home infusion, home health & hospice, skilled nursing, senior living)
Revenue
12%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Sleep and Breathing Health
Sleep apnea and respiratory care devices and related consumables (PAP, masks, ventilation) plus connected monitoring services
FY2026 revenue share uses Sleep and Breathing Health revenue of $4.977630bn divided by total revenue of $5.653443bn. Operating-profit share uses segment net operating profit of $2.204498bn divided by $2.422229bn. Source: https://www.sec.gov/Archives/edgar/data/943819/000094381926000047/rmd-20260630.htm
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
A large PAP and ventilation installed base supports recurring replacement cushions, headgear and accessories beyond the initial device sale. The advantage is moderate because patients can switch an entire mask system and competitors can supply compatible interfaces.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Philips re-entry and pricing pressure
- Reimbursement cuts and payer pressure
- Commoditization of masks/accessories
Leading indicators
- Masks and other revenue growth vs devices
- Gross margin trend in Sleep and Breathing Health
- Competitor share changes as Philips ramps
Counterarguments
- Masks/accessories can face price competition and multi-sourcing.
- Payers and consolidating DME providers can force price concessions.
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Connected devices and cloud applications generate patient monitoring data and embed ResMed in provider workflows (setup, adherence, population management), raising switching costs.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Interoperability/data portability reduces lock-in
- Cybersecurity incidents or privacy regulation changes
- Competitors replicate connected platforms
Leading indicators
- Connected device penetration / active patient monitoring users
- Deferred revenue tied to monitoring services
- Provider adoption of alternative platforms
Counterarguments
- Providers may insist on interoperable systems and device-agnostic monitoring.
- Connected features can become table-stakes rather than differentiators.
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Clinical markets emphasize reliability, support and reputation; trust matters in regulated therapy devices and long-term patient adherence.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Product quality issues/recalls
- Negative clinical outcomes or safety events
- Philips rehabilitates reputation over time
Leading indicators
- Field safety notifications / recall frequency
- Provider preference surveys
- Net promoter score / complaint rates (if disclosed)
Counterarguments
- Brand alone may not overcome large price gaps in a reimbursed market.
- Competitors can rebuild trust with new platforms and marketing.
Residential Care Software
Out-of-hospital care provider software (HME/home infusion, home health & hospice, skilled nursing, senior living)
FY2026 revenue share uses Residential Care Software revenue of $675.813m divided by total revenue of $5.653443bn. Operating-profit share uses segment net operating profit of $217.731m divided by $2.422229bn. On June 30, Resmed signed a $490m sale of MatrixCare, which contributed about $220m of FY2026 revenue and $55m of non-GAAP operating profit. It remains in historical results pending the expected Q1 FY2027 close; Brightree and MEDIFOX DAN are excluded. Sources: https://www.sec.gov/Archives/edgar/data/943819/000094381926000047/rmd-20260630.htm and https://www.sec.gov/Archives/edgar/data/943819/000119312526297658/d88958d8k.htm
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Workflow-embedded platforms (billing, EMR, analytics, engagement) become core operating systems for providers, raising switching costs and enabling cross-sell of adjacent modules.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Low barriers to entry and rapid product cycles
- Customers choose in-house systems or new vendors
- Data interoperability standards reduce switching costs
Leading indicators
- Net retention / renewal and expansion rates
- Churn among top customer cohorts
- Deferred revenue and remaining performance obligations trend
Counterarguments
- Company states the market is highly competitive with low barriers to entry.
- Providers can standardize on alternative suites if integration improves.
Evidence
Total Masks and other 2,085
FY2026 masks-and-other revenue reached approximately $2.085bn, confirming the scale of the recurring product stream.
Expanded our business by developing... mask systems... headgear and other accessories.
Product portfolio explicitly includes recurring accessories that pair with devices.
more than 30 million patients using cloud-connected devices on AirView
Quantifies the provider-facing connected installed base embedded in monitoring and therapy-management workflows.
Deferred revenue... relates... to... provision of data for patient monitoring.
Explicitly ties monetization to ongoing patient-monitoring data obligations.
Competitive factors are... quality, reliability and price... Customer support, reputation...
Company identifies reputation/support as key purchase factors.
Showing 5 of 10 sources.
Risks & Indicators
Erosion risks
- Philips re-entry and pricing pressure
- Reimbursement cuts and payer pressure
- Commoditization of masks/accessories
- Alternative therapies (GLP-1 drugs, nerve stimulation, surgery)
- Interoperability/data portability reduces lock-in
- Cybersecurity incidents or privacy regulation changes
Leading indicators
- Masks and other revenue growth vs devices
- Gross margin trend in Sleep and Breathing Health
- Competitor share changes as Philips ramps
- Connected device penetration / active patient monitoring users
- Deferred revenue tied to monitoring services
- Provider adoption of alternative platforms
Research RMD elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.